Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation antibodies engineered for prolonged activity in the body, formulated for delivery as monotherapies or combination therapies. These innovative antibodies target validated mechanisms to address inflammatory bowel disease (IBD) such as ulcerative colitis, as well as other immune-mediated diseases including gastrointestinal and rheumatic conditions. The company's pipeline includes programs like SPY001, currently in clinical trials such as the SKYLINE trial evaluating induction results in moderate-to-severe ulcerative colitis patients. Spyre Therapeutics focuses on creating disruptive solutions that offer potential improvements in efficacy and convenience for patients and caregivers dealing with high-burden immune-mediated disorders. Founded in 2013 and headquartered in Waltham, Massachusetts, Spyre Therapeutics plays a key role in advancing biotechnology innovations for underserved therapeutic areas in immunology.